Opinion|Videos|October 7, 2024
COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, discusses the updated data from the COMMANDS study presented at ASCO 2024, emphasizing the significance of outcome data comparing luspatercept to epoetin alfa in first-line (1L) treatment for lower-risk myelodysplastic syndromes (LR-MDS).
Advertisement
Episodes in this series
Video content above is prompted by the following:
Please discuss the updated data from the COMMANDS study presented at ASCO 2024.
- What is the importance of the outcome data for luspatercept vs epoetin alfa in 1L treatment? (
Zeidan et al, J Clin Oncol. 2024; 42(suppl 16): 6565 ); (Della Porta et al, Lancet Haematol. 2024; 11:e646-658 .)
Advertisement
Related to this article
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
4
Weighing Logistics and Time Savings of Subcutaneous Drug Delivery
5